Surrozen

San Francisco, United States Founded: 2016 • Age: 10 yrs
Selective Wnt agonists are developed for human tissue regeneration.
Annual revenue $10.7M Latest available
Total funding $133.0M 5 rounds
Employees 41 Tracked headcount
Investors 14 Known backers
Products 2 Services tracked
Competitors 9 Brand Intelligence

About Surrozen

Surrozen is a company based in San Francisco (United States) founded in 2016. Surrozen has raised $133 million across 5 funding rounds from investors including RA Capital, Hartford HealthCare and The Column Group. The company has 41 employees as of December 31, 2024. Surrozen offers products and services including Wnt Biology Platform and SWAP/SWEETS. Surrozen operates in a competitive market with competitors including Novartis, Catalent, Biotage, Curia and AmplifyBio, among others.

  • Headquarter San Francisco, United States
  • Employees 41 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Surrozen, Inc.
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $10.65 M (USD)
    0
    as on Dec 31, 2024
  • Net Profit
    -$63.56 M (USD)
    -47.68
    as on Dec 31, 2024
  • EBITDA
    -$24.1 M (USD)
    41.39
    as on Dec 31, 2024
  • Total Equity Funding
    $133 M (USD)

    in 5 rounds

  • Latest Funding Round
    $175 M (USD), Post-IPO

    Mar 24, 2025

  • Investors
    RA Capital

    & 13 more

  • Employee Count
    41

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Surrozen

Surrozen is a publicly listed company on the NASDAQ with ticker symbol SRZN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: SRZN · Sector: Health technology · USA

Products & Services of Surrozen

Surrozen offers a comprehensive portfolio of products and services, including Wnt Biology Platform and SWAP/SWEETS.

Product name locked
Category locked
Primary

Platform for unlocking body's regenerative power to treat injuries and diseases

Product name locked
Category locked
Locked

Technology for advancing treatments in regenerative medicine and disease pipelines

People of Surrozen

Headcount 50-200
Employee Profiles 19
Board Members and Advisors 14
Employee Profiles
People
Craig Parker
Chief Executive Officer
People
Charles Williams
Chief Operating Officer
People
Jay Villaluna
Associate Director, IT Infrastructure and Operations
People
Peter Stathis
Head Of Technical Operations

Unlock access to complete

Board Members and Advisors
people
Mary Haak-Frendscho
Director
people
Tim Kutzkey
Chairman
people
Bart Williams
Advisor
people
Chris Chai
Director

Unlock access to complete

Funding Insights of Surrozen

Surrozen has successfully raised a total of $133M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $175 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Surrozen

Surrozen has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Hartford HealthCare and The Column Group.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm focused on tech sectors
Locked Locked Locked
Early-stage investments in US life science startups are focused on.
Locked Locked Locked
Access Biotechnology is engaged in investing in transformative biopharma therapies.
Locked Locked Locked
Premium access

Investor details for Surrozen

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Surrozen

Investments
Premium access

Investment portfolio details for Surrozen

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Surrozen

Premium access

Detailed financials for Surrozen

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Surrozen Comparisons

Surrozen Primary company
Description
Selective Wnt agonists are developed for human tissue regene...
Location
San Francisco, United States
Founded Year
2016
Annual Revenue
$10.65 M (USD)
Net Profit
-$63.56 M (USD)
EBITDA
-$24.1 M (USD)
Employees
41
As of 2024
Premium access

Peer comparison for Surrozen

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Surrozen

Surrozen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Biotage, Curia and AmplifyBio, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
R&D focused on manufacturing of drugs for multiple therapeutic areas
Locked Locked Locked
CDMO offering drug and biologics development services
Locked Locked Locked
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
Locked Locked Locked
Drug research, development, testing, and consulting services are provided.
Locked Locked Locked
Provides contract research, development, and manufacturing services for biologic drugs.
Premium access

Detailed competitors of Surrozen

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Surrozen

Premium access

Complete news archive for Surrozen

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Surrozen

Surrozen was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Surrozen is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Surrozen is a funded company, having raised a total of $133M across 5 funding rounds to date.

As of Dec 31, 2024, the latest employee count at Surrozen is 41.

Annual revenue of Surrozen is $10.65M as on Dec 31, 2024.

Surrozen was founded in 2016 and is headquartered in San Francisco, United States. Protein therapeutics targeting the Wnt pathway are discovered and developed to support tissue repair and regeneration. A pipeline of selective agonists is constructed to enable in situ regeneration across various tissues. Roles of Wnt proteins in stem cell maintenance and developmental processes are leveraged within the biotechnology sector.

Surrozen's top competitors include Novartis, Catalent and Biotage.

Surrozen offers Wnt Biology Platform and SWAP/SWEETS.

Yes, Surrozen is publicly traded on NASDAQ under the ticker symbol SRZN.

Surrozen has 14 investors. Key investors include RA Capital, Hartford HealthCare, The Column Group, Venrock, and Access Biotechnology.

The ticker symbol of Surrozen is SRZN on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available